Anthem Biosciences: India's Largest Fermentation CRDMO at the Heart of Drug Discovery

July 14, 2026· 15 min read

India’s CDMO industry is on track to grow from roughly $23 billion today to nearly $58 billion by 2031, one of the fastest-growing pharma outsourcing markets in the world, expanding at close to double the global rate. Anthem Biosciences sits at the premium end of that build-out, offering the full CRDMO stack discussed below.

Anthem makes 14 commercial-stage molecules for global pharma: GLP-1 weight-loss drugs, the class behind Ozempic and Wegovy, antibody-drug conjugate cancer therapies, fermentation-derived enzymes, and biosimilars.

A destocking cycle hit the business in FY26 and the stock corrected, then a ₹1,274 crore block deal landed in June 2026, bought all at once by Premji Invest, SBI Mutual Fund, HDFC MF, Societe Generale, and a dozen other sophisticated names.

This is me trying to understand whether the thesis is intact. I hold the stock. Not investment advice. I’m learning out loud.

One caveat upfront: Anthem doesn’t disclose which specific molecules or clients it works on, most of that sits behind client NDAs, so nobody outside the company knows the exact pipeline. Everything here is built from what’s public: the DRHP, earnings calls, broker notes, and management interviews.

What Is a CRDMO?

CMO (Contract Manufacturing Organisation): manufactures a drug formula it’s handed, no intellectual input.
CRO (Contract Research Organisation): does early research, discovery, screening, trial support, no manufacturing.
CDMO (Contract Development and Manufacturing Organisation): process development, scale-up, and commercial manufacturing of a molecule someone else discovered.
CRDMO (Contract Research, Development and Manufacturing Organisation): all of it, discovery through commercial scale, one partner for the life of the molecule.

The standard CRDMO service map: small-molecule chemistry and large-molecule biologics, across the same discovery-to-manufacturing life cycle

Why outsource any of this at all? Building a compliant manufacturing plant from scratch takes years and hundreds of crores, and getting it FDA-approved, GMP certification, inspections, ongoing audits, is its own specialised discipline: one Warning Letter can shut down production entirely. A CRDMO’s facilities are already inspected and approved, so a client skips that multi-year qualification process. It also turns a fixed capital cost into a variable one: no plant to build before you even know if the drug works, and no idle capacity to carry if a molecule fails in trials, which is most of them.

The global CRO/CDMO market is roughly $254 billion (2025); the CRDMO subset is the smaller, faster-growing premium slice. India’s CDMO market is projected to grow from $23.3 billion in 2026 to ~$57.9 billion by 2031, a 14% CAGR against a 7-9% global average.

Part of that growth is geopolitical. The US BIOSECURE Act threatened to restrict American drug companies from working with large Chinese CDMOs (Wuxi Apptec, Wuxi Biologics) on national security grounds. That accelerated a China+1 shift already underway, and India, with a 30-40% cost advantage over the US/Europe and a deep pool of PhD chemists, is a credible destination for it.

Anthem calls itself a CRDMO because it genuinely offers all four capabilities under one roof, uncommon among Indian pharma companies, which are mostly generics manufacturers. The numbers back that up: 43.4% EBITDA margins and 23.7% ROE are both the best of any listed peer, alongside a revenue growth rate most of them can’t match.

Synthesis, Fermentation, and Specialty Ingredients

Three terms that recur throughout this post, worth getting straight now so the rest reads cleanly.

Custom synthesis is chemistry: building a molecule step by step from chemical building blocks, scaling from gram to kilogram to tonne. Capacity is measured in kilolitres (kL) of reactor volume.

Fermentation is biology: growing microorganisms (bacteria, fungi, yeast) in steel tanks and letting them produce the target molecule as part of their natural metabolism, the same basic idea as brewing beer. Each batch takes days to weeks, and the organism itself has to be engineered and tuned over years, which is why fermentation capacity is slow to build and hard for a competitor to replicate.

Specialty ingredients is Anthem’s other business line, separate from CRDMO contract work: probiotics, enzymes, and nutraceutical ingredients sold more like catalog products, not tied to one client’s proprietary molecule.

The Molecules Anthem Makes

GLP-1 peptides: the class behind Ozempic, Wegovy, and Mounjaro. Semaglutide is made in two steps, the peptide backbone grown through fermentation (engineered yeast), then a fatty-acid side chain attached through synthesis. Anthem’s Unit III (NeoAnthem) has a dedicated peptide facility.
Antibody-Drug Conjugates (ADCs): next-gen cancer treatments attaching a targeted antibody to a potent toxin (HPAPI). Requires biologics, HPAPI handling, and conjugation chemistry all at once. Anthem has a dedicated ADC practice and a hi-potent facility in Unit III.
Fermentation-derived molecules: statins, immunosuppressants, vitamins (including B7/biotin), enzymes, probiotics. Capital- and process-science-intensive, hard to replicate.
Small molecules via custom synthesis: Unit II at Harohalli, 376 kL, FDA-approved.
RNAi and oligonucleotides: next-gen gene-silencing therapeutics, small but growing.
Biosimilars: lower-cost versions of branded biologics post-patent, made commercially by Anthem.

Anthem isn’t a commodity manufacturer. It works some of the most complex, highest-margin therapeutics in global pharma, and that’s what underpins the 43% EBITDA margins.

All of this runs across three operating units today (I, II, and III). A fourth, a 30-acre site bigger than the other three combined, is now being provisioned: Phase 1 alone targets roughly a doubling of custom synthesis capacity and 50% more fermentation capacity, on top of what’s already running.

The Story: From Biocon to ₹42,000 Crore

1980s–2005: Ajay Bhardwaj studies chemical engineering at IIT Delhi, does graduate work at Louisiana State University, and in 1986 takes a pay cut to join Biocon under Kiran Mazumdar-Shaw, who would go on to become India’s first self-made female billionaire. He spends 20 years there, rising to senior leadership. When an expected promotion doesn’t come through, he quits.

2006: At 46, with two kids headed to university, he sells his 1% Biocon stake, takes a bank loan, and puts roughly $9 million of his own money into Anthem Biosciences. No external investors, no safety net. His bet: global pharma companies were being squeezed by rising R&D costs and falling approval rates, and outsourcing the entire development-and-manufacturing process, not just manufacturing, was the answer. India had the chemistry talent; nobody was building a comprehensive end-to-end platform for it.

2006–2020: Building the capabilities from scratch. Fermentation was central to the thesis from day one, the hardest, most capital-intensive part of the business. Most labs avoid it; Anthem leaned in.

2020–2025: Revenue compounds at ~32% annually (FY23–FY25). Commercial molecule count builds steadily, reaching 10 by FY25.

July 2025: IPO at ₹570/share, 67x oversubscribed, lists at ₹723 (+27% on day one). Bhardwaj, now 65, appears on Forbes’ Billionaires list at $2.4 billion net worth.

The $9 million gamble at 46 became $2.4 billion by 65.

The Fermentation Moat

Fermentation capacity: Anthem is roughly 6x the next-largest Indian CRDMO

Fermentation capacity: ~180 kL (FY26, after Unit III fermentation block completion)
Custom synthesis capacity: 425 kL across Units I, II, and III (76 kL Unit II block completed November 2025)
Second-largest Indian CRDMO’s fermentation capacity: ~30 kL, so Anthem is six times larger

Among global CRDMOs with meaningful fermentation capability, it’s a short list. Among Indian companies, Anthem is in a different category, one a competitor can’t close in five years.

The Molecule Flywheel

This is the central compounding mechanism, what makes a CRDMO structurally different from a contract manufacturer. A molecule that moves from discovery through Phase 1-3 trials brings growing manufacturing volumes, and at commercial launch the contract can last decades. Every molecule Anthem takes from discovery to commercial scale generates recurring revenue tied to how well the drug sells. If it becomes a blockbuster, Anthem is making it for years.

Anthem’s pipeline, per the Q4 FY26 call (May 20, 2026) and Nomura’s initiating coverage (November 2025):

100+ early-stage programs in R&D (the Q3 call had cited ~130-140; the funnel composition shifts quarter to quarter)
10 molecules in Phase 3. Baig walked through the mechanics: 10 in late-stage Phase 3 at the start of FY26, four graduated to commercial during the year, a few new ones added, count ended the year back at 10. Anthem’s own Q1 FY26 results confirm the first leg of this: Phase 3 already down to 8 and commercial up to 12 within that single quarter
14 commercial molecules (up from 10 the prior year, 4 newly commercialised in FY26)
Four recent commercialisations with a combined peak market sales estimate of ~$10 billion
Six commercial molecules with combined end-market sales of ~$12 billion (2024), projected to reach ~$24 billion by CY2029, per Nomura’s analysis

Q1 FY26 results confirm the mechanics: two molecules graduated Phase 3 to commercial that quarter alone (10→8 and 10→12); by year-end, new candidates had backfilled Phase 3 to 10 while commercial molecules reached 14

GLP-1 sits inside this pipeline, still early. Bhardwaj on the Q4 call:

“If you follow the GLP approvals in India, most of them have their active [ingredient] from China. Now we are in conversations with, I would say, all the big players to give them an alternate, which is based here in India.” … “After most of them have launched, we will be in a good place to replace imports.” … Anthem’s cost of goods on GLP-1-type peptides is “extremely competitive, rivalling even the Chinese.”

Brand-side competition in India is already crowded (40-50 generic semaglutide brands expected following the March 2026 patent expiry), but the manufacturing side stays scarce, only a handful of Indian companies can make the API at scale, which is the gap Anthem is positioning to fill. None of the peak-sales figures above yet include a GLP-1 launch; it’s optionality sitting on top of the existing pipeline. On timing, Bhardwaj was loose: “it could happen in six months, it could happen in eight months.”

That $24 billion figure is not Anthem’s revenue and not company guidance, it’s an analyst’s projection of the market size of the drugs Anthem manufactures for. Even capturing manufacturing margins on a fraction of that is substantial recurring revenue. The risk is attrition: molecules fail in trials, programmes get terminated, clients switch partners. But with 100+ early-stage programs and 10 in Phase 3, the funnel is wide enough that normal attrition still produces meaningful commercialisations.

The Numbers

Year	Revenue	PAT	EBITDA%	PAT%
FY23	~₹1,058 Cr	~₹230 Cr	~32%	~22%
FY24	~₹1,397 Cr	~₹320 Cr	~35%	~23%
FY25	₹1,844 Cr	₹452 Cr	~37%	~24.5%
FY26	₹2,124 Cr	₹592 Cr	43.4%	26.0%

FY23/FY24 are estimates from the ~32% FY23–FY25 revenue CAGR; FY25/FY26 are confirmed. EBITDA%/PAT% are on total income (revenue + other income, ₹2,280 Cr for FY26), the basis management uses on calls, not a direct division of the Revenue column.

The margin expansion from ~32% EBITDA in FY23 to 43.4% in FY26 is the standout, as commercial molecules become a larger share of the mix. Q4 FY26 at 48.1% EBITDA is a preview of where that mix could take the business.

Debt: Debt/Equity of 0.05, essentially debt-free. ROE: 23.7% (FY26). Returns this strong at near-zero leverage are rare, and the clean balance sheet is what makes the coming ₹1,200 crore Unit IV capex feasible without equity dilution.

Capex: ₹188 Cr (FY23), ₹296 Cr (FY24), ₹264 Cr (FY25), funding the Unit II/III expansions below. On the Q4 call, CFO Gawir Baig guided FY27 capex at roughly ₹700 crore (bulk of the ₹1,200 crore Unit IV Phase 1 spend, plus residual Unit II/III and maintenance), stepping down to ~₹500 crore in FY28.

The Central Thesis: Destocking, Recovery, Restocking

This is the most important section for understanding why the stock is where it is.

What is destocking? Pharma companies and distributors carry inventory buffers. When they anticipate strong demand, they overstock; when buffers are full, they work through existing stock before ordering more (destocking). The CRDMO sees this as a sudden drop in volumes, not because underlying drug demand fell, but because the ordering cycle paused. It’s a known dynamic in CRDMO, but it can be sharp: molecules don’t stop selling, orders just stop arriving temporarily.

FY26 Quarter by Quarter

Quarterly revenue, FY26: the Q3 dip is the destocking hit; Q4 is a record quarter even with some destocking still lingering

Quarter	Revenue	YoY	EBITDA%	PAT%	What Happened
Q1 FY26	₹540 Cr	+60%	38.0%	24.0%	Pre-IPO demand surge; strong commercial volumes
Q2 FY26	₹550 Cr	~+5%	44.5%	29.0%	Momentum continues; margin expansion visible
Q3 FY26	₹423 Cr	-15%	41.8%	20.3%	Destocking hits. CRDMO revenue -19.4% YoY. Guidance cut
Q4 FY26	₹611 Cr	+26%	48.1%	28.7%	Restocking begins. Record quarter. PAT +130% YoY
FY26	₹2,124 Cr	+15.2%	43.4%	26.0%	Full year muted by Q3; exit rate strong

EBITDA%/PAT% are on total income, matching how management reports margins on calls.

The Q3 crash was specifically in the CRDMO segment (-19.4% YoY); Speciality Ingredients was resilient (+6.7% YoY the same quarter). That tells you the destocking was a customer ordering-cycle issue, not a structural problem with Anthem’s capabilities or client relationships. Management revised full-year guidance from 20% to 15-16% mid-quarter, and the stock corrected.

Three of the four quarters ran at or above the original 20% guide (Q1 +60%, Q2 +5%, Q4 +26%). Only Q3 broke the pattern, for an ordering-cycle reason, not a demand or execution one. Strip that one quarter out and the trajectory looks much closer to 20% than the headline 15.2% suggests. CFO Gawir Baig said as much on the Q4 call:

“Historically, if you look at it last 10 years, our revenue growth has been around 20% level. Even when we started last year, we said that we’ll be delivering about 20%, but then… we delivered about 15% revenue growth. While we had said 20% on revenues and 20% on EBITDA and PAT, whatever was the shortfall on revenues, we more than made up with respect to our EBITDA and PAT performance, with a 30% EBITDA growth and 30% plus PAT growth for FY26.”

Q4 FY26: The Reversal

Q4 was the highest revenue quarter in company history: 48.1% EBITDA margin (a record), PAT +130% YoY, CRDMO revenue +31% YoY. Management’s language hedges slightly, Bhardwaj called destocking “mostly” behind the company, then added elsewhere: “The destocking that had to happen has already happened… they are restocking now. That part is behind us.” Read together: the bulk of the drag has cleared, with room for some residual effect. Even so, Q4 was the strongest quarter on record.

Competitors

No listed Indian company is a clean comparable to Anthem at the CRDMO level.

Company	Trailing PE	ROE	EBITDA%	Fermentation	ADC/Peptides	RNAi
Anthem Biosciences	71.9x	23.7%	43.4%	✅ 180 kL	✅ Full	✅
Syngene International	~55x	~10%	~25%	❌	Partial	❌
Divi’s Laboratories	~70x	16.2%	~30–32%	❌	❌	❌
Sai Life Sciences	~65x	8.7%	~30%+	Partial	✅	❌
Neuland Laboratories	~64x	n/a	~29%	❌	Partial	❌
Concord Biotech	~54x	17.7%	~36–40%	✅	❌	❌

Valuation

Anthem trades at approximately 71.9x trailing PE on FY26 PAT of ₹592 crore. Market cap is ~₹42,524 crore at ₹750/share (~56.7 crore shares outstanding), or ~20x FY26 revenue, a technology-company multiple applied to a manufacturing business. That’s not cheap by any measure, and it’s the highest trailing PE of the peer set above. For context, Divi’s is ~70x, Syngene ~55x, Neuland ~64x, Concord ~54x: Anthem’s multiple is broadly in line with the sector, notably Divi’s trades at nearly the same PE despite growing at ~12% with zero next-generation modality capability.

ROE of 23.7% is the highest among listed Indian CRDMOs and notably strong for a business that’s almost debt-free.

Management is confident in sustaining 20%+ growth but hasn’t given specific FY27 guidance. At 20% PAT growth, FY27 PAT would be approximately ₹710 crore.

FY27 Forward PE	Implied Market Cap	Share Price	vs ₹750
50x	₹35,500 Cr	₹626	-17%
60x	₹42,600 Cr	₹751	flat
71.9x (current trailing)	₹51,049 Cr	₹900	+20%
85x	₹60,350 Cr	₹1,064	+42%

The honest read: at 71.9x trailing PE, there’s limited room for error, as Q3 FY26 showed. But the Q4 recovery, record margins, block-deal buyers, and restocking dynamic ahead all point to FY27 delivering a materially better full year than FY26.

Shareholding: Smart Money Building

	Jul '25 (listing)	Dec '25	Mar '26	Jun '26 (post block deal)
Promoter	~76%	~75%	74.7%	71.6%
FII	~0.5%	~1.1%	1.3%	↑ building
DII	~7%	~10%	11.5%	↑ building
Public	~16%	~13%	12.5%	↓ declining

Listing-period and Dec ’25 figures are approximate. Jun ’26 promoter figure is confirmed (71.63%); the FII/DII breakdown isn’t yet published.

DII holding has built steadily from 7% at listing to 11.5% by March 2026; FII at 1.3% is still early, with room to run if global funds start engaging the India CRDMO story. The June block deal added Societe Generale, Nordea, and Prudential to the foreign register. The pattern throughout: institutions accumulating, retail declining, promoter selling through secondary transactions (not dilution), by sophisticated long-term holders, not traders.

The Block Deal: Who Bought the Dip

On June 18, 2026, with the stock at ₹744-750 following the Q3 correction, a ₹1,274 crore block deal executed: 1.71 crore shares at ₹744.80, a 3.05% stake. Seller: Aruna Ganesh (promoter family); promoter holding dropped from 74.68% to 71.63%.

Buyers included Premji Invest (via PI Opportunities AIF V), SBI, HDFC, Kotak Mahindra, and UTI mutual funds, foreign institutions Societe Generale, Nordea, and Prudential (Hong Kong), plus Kotak, Bajaj, and ICICI Prudential life insurance. Per-institution amounts aren’t disclosed, only the aggregate and buyer list.

That’s a roster of sophisticated institutional buyers, not retail momentum, buying specifically after management signalled destocking was over and restocking was expected. That’s the market’s vote on the thesis.

The Expansion: From 425 kL to Doubling

Unit I (Bommasandra): 24 kL custom synthesis. Original facility, FDA-approved.
Unit II (Harohalli): 376 kL custom synthesis, FDA-approved. Includes a 130 kL FY26 expansion (54 kL block early in the year, final 76 kL block in November 2025), guided by management as over ₹300 crore of incremental revenue potential once fully ramped.
Unit III (NeoAnthem, Harohalli): 25 kL custom synthesis plus peptide and hi-potent (ADC) manufacturing. Fermentation block operational (~180 kL total across Units I–III) and generating revenue, with peptide/HPAPI still ramping. Some of the Unit II/III expansion spend was still capital work-in-progress on the books into H1 FY27, capacity is running, but not all the investment behind it is fully capitalised yet.
Unit IV (Greenfield): 30-acre site, Anthem’s largest project to date, bigger than Units I–III combined. ₹1,200 crore Phase 1 spread across FY27-FY28, targeting roughly a doubling of custom synthesis capacity (+~365 kL) and ~50% more fermentation capacity (+~100 kL), plus a dedicated Food and Nutraceutical facility. Target completion March 2028.

Unit IV is being built in anticipation of the 10 Phase 3 molecules commercialising. If they launch successfully over FY27-29, Anthem needs the capacity ready; if late, it risks losing contracts to competitors.

Bull Case

Fermentation moat is real and structural. 180 kL vs ~30 kL for the next Indian CRDMO, two decades of process science, not replicable quickly.
The destocking thesis is playing out as expected. Q3 hit, Q4 recovered, restocking ahead. The block deal buyers read this cycle correctly.
Molecule flywheel is already delivering. 14 commercial molecules, 4 added in FY26, tied to drugs with a combined $24 billion peak market potential across six of them, Anthem’s revenue is a manufacturing-margin slice of that, not the number itself.
GLP-1 and ADC are the fastest-growing segments in global pharma right now, and Anthem has dedicated infrastructure for both.
Q4 FY26 exit rate tells the real story. ₹611 Cr in a quarter, 48.1% EBITDA, a ₹2,444 crore annualised run rate entering FY27. 20% FY27 growth from there isn’t a stretch.
ROE of 23.7% at near-zero leverage, and Unit IV isn’t even deployed yet.
China+1 / BIOSECURE is a structural, multi-year tailwind, and Anthem’s US relationships via DavosPharma position it as a beneficiary.
Smart money bought the dip. Premji Invest, SBI MF, HDFC MF, Societe Generale, Nordea, all at ₹744.80 in June 2026.

Risks

Sourced from the IPO DRHP, Q3/Q4 FY26 call transcripts, and initiating coverage from Nomura (November 2025) and PL Capital.

This has happened before. Revenue fell 14.2% from FY22 (₹1,231 Cr) to FY23 (₹1,057 Cr) after a Phase 3 molecule failed and a commercialised molecule was withdrawn. Not hypothetical, Anthem has lived both within three years.
Product concentration. Nomura flagged the top two products at an estimated 36-38% of revenue through FY26-FY28. Q3 FY26 showed exactly what happens when one enters a destocking cycle: a 15% revenue decline in a single quarter.
Customer concentration. Per the DRHP, top 5 clients = 70.92% of FY25 revenue, top 10 = 77.33%. The company’s own disclosure says losing even one large client would materially impact cash flows.
DavosPharma: three risks in one. It’s simultaneously Anthem’s exclusive US marketing/distribution channel, a related party (affiliate of a shareholder), and was a selling shareholder in the IPO. Also the third-largest customer at 14.28% of FY25 revenue. A breakdown here disrupts all US business with no immediate alternative channel.
Patent expiry. Patent-protected molecules contributed 38.83% of FY23 revenue; several current commercial molecules sit within a 10-year patent horizon, after which generics enter and volumes decline. Worth noting this cuts both ways: the same dynamic is what’s fuelling the GLP-1 opportunity, semaglutide’s March 2026 patent expiry is precisely why 40-50 generic brands are now launching in India, each of them needing a manufacturer.
No FY27/FY28 guidance. Management withheld specific guidance on both the Q3 and Q4 calls, and the Q3 call already cut guidance mid-year from 20% to 15-16%. At 71.9x trailing PE, the absence of an anchor number means any miss creates disproportionate sentiment damage.
Regulatory/FDA inspection risk. All three facilities are FDA-approved and export to regulated markets; an adverse inspection outcome could shut or constrain a unit, with the DRHP flagging the geographic concentration (all facilities in Bengaluru) as a specific risk.
Scientific talent attrition. Nomura calls out attrition of scientists as a risk; Anthem currently runs below industry attrition, but competition for PhD chemists and fermentation scientists will only rise as more Indian CRDMOs expand.
Valuation. At 71.9x trailing PE, there’s limited buffer if earnings growth disappoints for even a quarter or two.

My Take

The story is specific and testable: a destocking hit in Q3 FY26, management saying it’s behind them and restocking is coming, and a ₹1,274 crore block deal executed at ₹744.80 by some of the most sophisticated institutional investors in India and globally. If that thesis plays out in FY27, the Q4 exit rate compounds, CRDMO re-accelerates toward 20%+, and the FY26 full-year numbers end up looking like an anomaly caused by an ordering cycle, not the underlying business.

The moat is clear: 180 kL of fermentation capacity, six times the next Indian player, integrated CRDMO from discovery to commercial, and blockbuster exposure in two of pharma’s highest-growth categories, GLP-1 and ADC. That combination doesn’t come along often. The valuation concern is real too, at 71.9x trailing PE every rupee of future earnings is already priced in, but a 23.7% ROE on a near-debt-free balance sheet suggests Unit IV’s incremental returns should be very high.

What I’m watching: does Q1 FY27 revenue confirm restocking, how does Unit III fermentation contribute through FY27, and do any of the 10 Phase 3 molecules commercialise. I hold the stock, and the block deal buyers have made their view explicit too. Still watching closely.

None of this is investment advice. I am learning out loud.

This post was researched and written with the help of AI. All figures have been cross-checked against public sources, but do your own verification before making any decisions.

Sources: